Alvotech (ALVO) Reports Prelim Q2 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Deutsche Bank Reiterates Hold Rating on Alvotech SA (ALVO), 'we continue to monitor ongoing Simlandi RX trends in the US'
July 2, 2024 1:02 PM EDTDeutsche Bank analyst Emmanuel Papadakis reiterated a Hold rating and $14.00 price target on Alvotech SA (NASDAQ: ALVO).
The analyst comments "ALVO yesterday reported a Q2 sales beat of c41%/c31% for DB/cons, respectively. Top-line performance was primarily driven by achievement of clinical... More



